Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
Lisata Therapeutics (Nasdaq: LSTA) highlighted positive preclinical results on November 4, 2025 after Catalent presented data at the 16th Annual World ADC San Diego Conference (Nov 3–6, 2025).
Catalent reported that incorporating Lisata’s proprietary iRGD cyclic peptide certepetide as a non-cytotoxic payload in its SMARTag® ADC platform improved tumor-selective penetration and broadened intratumoral distribution of cytotoxic payloads, and also enhanced ADC efficacy in preclinical models. Lisata emphasized this finding as supportive of its licensing partnership with Catalent and its strategy to use certepetide to boost therapeutic delivery across modalities.
Lisata Therapeutics (Nasdaq: LSTA) ha evidenziato risultati preclinici positivi il 4 novembre 2025 dopo che Catalent ha presentato dati alla 16ª World ADC San Diego Conference (3–6 novembre 2025).
Catalent ha riferito che l'integrazione del peptide ciclico proprietario iRGD di Lisata, certepetide, come payload non citotossico nella sua piattaforma SMARTag® ADC ha migliorato la penetrazione selettiva nei tumori e ha ampliato la distribuzione intratumorale dei payload citotossici, e ha anche potenziato l'efficacia degli ADC in modelli preclinici. Lisata ha sottolineato questa scoperta come supporto alla sua partnership di licensing con Catalent e alla sua strategia di usare certepetide per potenziare la somministrazione terapeutica attraverso le modalità.
Lisata Therapeutics (Nasdaq: LSTA) destacó resultados preclínicos positivos el 4 de noviembre de 2025 después de que Catalent presentara datos en la 16ª World ADC San Diego Conference (del 3 al 6 de noviembre de 2025).
Catalent informó que incorporar el péptido cíclico proprietário iRGD de Lisata, certepetide, como payload no citotóxico en su plataforma SMARTag® ADC mejoró la penetración selectiva tumoral y amplió la distribución intratumoral de payloads citotóxicos, y también potenció la eficacia de los ADC en modelos preclínicos. Lisata enfatizó este hallazgo como apoyo a su asociación de licencias con Catalent y a su estrategia de utilizar certepetide para impulsar la entrega terapéutica a través de las modalidades.
Lisata Therapeutics (Nasdaq: LSTA)가 2025년 11월 4일에 양성의 전임상 결과를 강조했고, Catalent가 2025년 11월 3일부터 6일까지 샌디에이고에서 열린 제16회 World ADC San Diego Conference에서 데이터를 발표한 후에였습니다.
Catalent는 Lisata의 독점적인 iRGD 고리형 펩타이드 certepetide를 비독성 페이로드로 SMARTag® ADC 플랫폼에 도입하면 종양 선택적 침투가 개선되고 종양 내 전달 분포가 확장되며, 또한 전임상 모델에서 ADC 효능이 향상되었다고 보고했습니다. Lisata는 이 발견을 Catalent와의 라이선스 파트너십 및 다양한 모달리티를 통한 치료 전달 증진 전략에 대한 지지로 강조했습니다.
Lisata Therapeutics (Nasdaq : LSTA) a mis en évidence des résultats précliniques positifs le 4 novembre 2025 après que Catalent ait présenté des données lors de la 16e World ADC San Diego Conference (du 3 au 6 novembre 2025).
Catalent a rapporté que l'incorporation du peptide cyclique propriétaire iRGD de Lisata, certepetide, en tant que payload non cytotoxique dans sa plateforme SMARTag® ADC a amélioré la pénétration sélective tumorale et élargi la distribution intratumorale des payloads cytotoxiques, et a également renforcé l'efficacité des ADC dans des modèles précliniques. Lisata a souligné cette constatation comme un soutien à son partenariat de licence avec Catalent et à sa stratégie d'utiliser certepetide pour booster la délivrance thérapeutique à travers les modalités.
Lisata Therapeutics (Nasdaq: LSTA) hob am 4. November 2025 positive präklinische Ergebnisse hervorgehoben, nachdem Catalent Daten auf der 16. World ADC San Diego Conference (3.–6. November 2025) präsentiert hatte.
Catalent berichtete, dass die Einbindung des proprietären iRGD-zirkulären Peptids von Lisata, certepetide, als nicht cytotoxische Payload in seine SMARTag® ADC-Plattform die tumorspezifische Penetration verbessert und die intratumorale Verteilung zytotoxischer Payloads erweitert und zudem die Wirksamkeit von ADC in präklinischen Modellen verbessert habe. Lisata hob diese Feststellung als Unterstützung für seine Lizenzpartnerschaft mit Catalent und seine Strategie hervor, certepetide zu nutzen, um die therapeutische Lieferung über Modalitäten hinweg zu verbessern.
Lisata Therapeutics (ناسداك: LSTA) سلطت الضوء على نتائج ما قبل السريرية الإيجابية في 4 نوفمبر 2025 بعد أن قدمت Catalent بيانات في المؤتمر العالمي الـ16 لـ World ADC سان دييغو (3–6 نوفمبر 2025).
أفادت Catalent أن دمج الببتيد الحلقي iRGD المملوك لـ Lisata، certepetide كحمولة غير سامة في منصتها SMARTag® ADC حسّن الاختراق الورمي الانتقائي ووسع التوزيع داخل الورم للحمولات السامة للخلايا، كما عزز فاعلية الـ ADC في نماذج ما قبل السريرية. أكدت Lisata أن هذا الاكتشاف يدعم شراكتها في الترخيص مع Catalent واستراتيجيتها لاستخدام certepetide لتعزيز توصيل العلاج عبر المنظورات المختلفة.
- Preclinical data showed improved tumor-selective penetration using certepetide
- Preclinical data showed enhanced ADC efficacy when certepetide was incorporated
- Licensing partnership with Catalent confirmed and leveraged on Nov 4, 2025
- Data are preclinical only; human safety and efficacy not demonstrated
- Results were presented by Catalent at a conference, not from a Lisata clinical trial
Insights
Positive preclinical ADC payload data for certepetide, but impact remains conditional on clinical translation.
Lisata and licensing partner Catalent reported that incorporating certepetide as a non‑cytotoxic payload in Catalent's SMARTag® ADC platform improved tumor‑selective penetration and increased ADC efficacy in preclinical models, with the findings presented at the
The principal dependencies are clear and contained in the disclosed facts: preclinical efficacy and distribution gains must translate to acceptable safety and preserved payload activity in vivo, and any commercial or clinical value depends on further development by Catalent under the existing license. Risks remain inherent in the preclinical-to‑clinical gap; no clinical or human safety data were reported, and no new regulatory milestones or financial terms were disclosed.
Watch for subsequent disclosures from Catalent or Lisata showing dose‑response, systemic safety, and any planned clinical study initiation or partnering/commercial terms; near‑term signals would come from follow‑on preclinical datasets and formal development plans expected in the coming development cycle.
Data from Catalent’s preclinical studies evaluating certepetide as a SMARTag® ADC payload showed both improved tumor selective penetration and efficacy
BASKING RIDGE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today highlighted positive preclinical data as announced by Lisata’s licensing partner, Catalent, Inc. (“Catalent”), at the 16th Annual World ADC San Diego Conference, held November 3-6, 2025. Catalent’s presentation included data demonstrating the positive impact of incorporating Lisata's proprietary iRGD cyclic peptide product candidate, certepetide, and its analogs as a payload in Catalent’s SMARTag® antibody-drug conjugate (“ADC”) technology platform. Specifically, Catalent reported preclinical results showing that using certepetide as a non-cytotoxic ADC payload not only improved ADC efficacy but also broadened the distribution of the cytotoxic payload within the tumor microenvironment. A summary of these results can be found here in the Company’s latest corporate presentation.
“This data is encouraging as it reinforces the large and growing body of evidence indicating that certepetide can enhance the targeting, penetration, and effectiveness of therapeutic agents - in this case, ADCs - in which it is chemically incorporated or co-administered,” stated Kristen K. Buck, M.D., Executive Vice President of Research and Development and Chief Medical Officer of Lisata. “ADCs are one of the fastest growing and most exciting therapeutic categories in drug development. These results underscore our belief in the value of our licensing partnership with Catalent and supports our strategy of leveraging certepetide’s unique mechanism to enhance the therapeutic potential across all modalities of treatments.”
Lisata licensed certepetide and its analogs to Catalent for use with its SMARTag® technology platform, as part of its Enhanced Conjugates innovations. Enhanced Conjugates are designed to amplify the effect of a cytotoxic payload by combining it with a non-cytotoxic payload, such as certepetide, with the goal of amplifying efficacy without compromising safety.
About Certepetide
Certepetide (formerly LSTA1), an internalizing RGD (arginyl-glycyl-aspartic acid or iRGD), cyclic peptide product candidate, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor. Certepetide also has been shown to modify the tumor microenvironment resulting in tumors which are more susceptible to immunotherapies. We and our collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics. To date, certepetide has also demonstrated favorable safety, tolerability, and clinical activity in completed and ongoing clinical trials designed to test its ability to enhance the effectiveness of standard-of-care chemotherapy for pancreatic cancer. Lisata is exploring the potential of certepetide to enable a variety of treatment modalities to treat a range of solid tumors more effectively. Certepetide has been awarded Fast Track designation (U.S.) and Orphan Drug Designation for pancreatic cancer (U.S. and E.U.) as well as Orphan Drug Designation for glioma (U.S.) and osteosarcoma (U.S.). Additionally, certepetide has received Rare Pediatric Disease Designation for osteosarcoma (U.S.).
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform® technology. The Company expects to announce numerous milestones over the next 1.5 years and believes that its projected capital will fund operations into the first quarter of 2027, encompassing anticipated data milestones from its ongoing clinical trials. For a comprehensive overview of certepetide's mechanism of action, please view our informative short film. For more information on the Company, please visit www.lisata.com.
Forward-Looking Statements
This communication contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding the Company’s clinical development programs are forward-looking statements. In addition, when or if used in this communication, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Lisata or its management, may identify forward-looking statements. Examples of forward-looking statements include, but are not limited to, the potential efficacy of certepetide as a treatment for patients with solid tumors; our beliefs about the potential uses and benefits of certepetide; the potential of the collaboration with Catalent to develop new treatment options; the expected expiration of our patents for certepetide; our ability to obtain patent term extension on our U.S. composition of matter patent; statements relating to Lisata’s continued listing on the Nasdaq Capital Market; expectations regarding the capitalization, resources and ownership structure of Lisata; the approach Lisata is taking to discover and develop novel therapeutics; the adequacy of Lisata’s capital to support its future operations and its ability to successfully initiate and complete clinical trials; and the difficulty in predicting the time and cost of development of Lisata’s product candidates. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: results observed from preclinical or preliminary data are not necessarily indicative of final results and one or more of the clinical outcomes may materially change following more comprehensive reviews of the data and as more patient data becomes available, including the risk that unconfirmed responses may not ultimately result in confirmed responses to treatment after follow-up evaluations; the risk that product candidates that appeared promising in early research, preclinical studies, and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials; the safety and efficacy of Lisata’s product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in Lisata’s clinical programs, Lisata’s ability to finance its operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of Lisata’s scientific studies, Lisata’s ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in Lisata’s markets, the ability of Lisata to protect its intellectual property rights; and legislative, regulatory, political and economic developments. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in Lisata’s Annual Report on Form 10-K filed with the SEC on February 27, 2025, and in other documents filed by Lisata with the Securities and Exchange Commission. Except as required by applicable law, Lisata undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
Media and Investors:
Lisata Therapeutics
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com
This press release was published by a CLEAR® Verified individual.
FAQ
What did Lisata (LSTA) announce on November 4, 2025 about certepetide?
How does certepetide affect ADC performance according to the Nov 2025 report?
Was the certepetide data presented at a conference or released as a Lisata clinical result?
Does the Nov 4, 2025 announcement show human trial results for LSTA therapies?
What is the strategic significance of the Catalent licensing partnership for Lisata (LSTA)?
